改善骨髓纤维化造血干细胞移植结局的创新策略
骨髓纤维化(MF)是一种克隆性骨髓增殖性肿瘤,异基因造血干细胞移植是唯一可能治愈的手段,但近二十年来其他移植适应症的生存改善未能在MF中实现。本文综述了疾病慢性炎症对终末器官功能评估的要求、分子疾病分级异质性以及先进预后模型和分子诊断等工具,提出可能改善MF移植结局的创新策略,并指出需要开展考虑分子疾病分级影响的大样本前瞻性研究。
要点
- 异基因造血干细胞移植是MF唯一可能治愈的疗法,但近二十年其生存改善未达其他移植适应症水平。
- MF的慢性炎症状态要求移植前评估终末器官功能,直接套用其他髓系疾病的移植方法未考虑其病理生理差异。
- 分子疾病分级存在异质性,需结合先进预后模型和分子诊断探索改善移植结局的策略。
核心结论
- 探索MF慢性化特有的生理后果、承认疾病分级异质性并应用先进预后模型、分子诊断和其他器官功能诊断工具,可能改善该病移植结局。
- 需要开展考虑分子疾病分级影响的大样本前瞻性研究用于MF移植。
研究设计与样本
- 本文为综述,检索范围未在原文中报告。
主要发现
- 近二十年来其他移植适应症观察到的生存获益未能在MF中实现。
- 对MF移植结局不佳原因的认识有限,阻碍了MF移植入选标准的完善。
- 越来越多证据表明分子疾病分级存在异质性,超出传统上指导移植时机的临床表现。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelofibrosis (MF) is a clonal myeloproliferative neoplasm characterized by inflammation, marrow fibrosis, and an inherent risk of blastic transformation. Hematopoietic allogeneic stem cell transplant is the only potentially curative therapy for this disease, however, survival gains observed for other transplant indications over the past two decades have not been realized for MF. The role of transplantation may also evolve with the use of novel targeted agents. The chronic inflammatory state associated with MF necessitates pretransplantation assessment of end-organ function. Applying the transplant methodology employed for other myeloid disorders to patients with MF fails to acknowledge differences in the underlying disease pathophysiology. Limited understanding of the causes of poor transplant outcomes in this cohort has prevented refinement of transplant eligibility criteria in MF. There is increasing evidence of heterogeneity in molecular disease grade, beyond the clinical manifestations which have traditionally guided transplant timing. Exploring the physiological consequences of disease chronicity unique to MF, acknowledging the heterogeneity in disease grade, and using advanced prognostic models, molecular diagnostics and other organ function diagnostic tools, we present an innovative review of strategies with the potential to improve transplant outcomes in this disease. Larger, prospective studies which consider the impact of molecular-based disease grade are needed for MF transplantation.
引用
- Perram J, Ross DM, McLornan D, et al. Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis. Am J Hematol. 2022. PMID: 35802782. doi:10.1002/ajh.26654
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。